Inhibitory effects of Korean red ginseng and its genuine constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models.
The inhibitory effects of the Korean red ginseng (steamed root of Panax ginseng C.A. MEYER, family Araliaceae) saponin fraction (KRGS) and its constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis (PCA) and contact dermatitis models were measured. Orally administered KRGS and its genuine ginsenosides potently inhibited the PCA reaction induced by IgE. However, when these ginsenosides were intraperitoneally administered, ginsenoside Rh2 showed the most potent inhibition. The ginsenoside Rh2 also the most potently inhibited the beta-hexosaminidase release from RBL-2H3 cells induced by IgE with antigen. KRGS administered topically at a dose of 0.1% suppressed ear swelling in an oxazolone-induced mouse contact dermatitis model by 38.8%. Its constituents ginsenosides Rg3, Rf, and Rh2 at a concentration of 0.05% also potently suppressed mouse ear swelling by 47.5%, 34.8%, and 49.9% at 16 d, respectively. These ginsenosides also significantly reduced mRNA expression levels of cyclooxygenase (COX)-2, interleukin (IL)-1beta, tumor necrosis factor-alpha and interferon-gamma induced by oxazolone applied to mouse ears. However, the ginsenosides, except for ginsenoside Rh2, almost did not notably reduce IL-4 levels. The ginsenoside Rh2 also potently inhibited COX-2 and inducible NO synthetase protein expression in liphopolysaccharide-stimulated RAW264.7 cells. Based on these findings, KRGS and its ginsenosides are suggested to improve atopic and contact dermatitis by regulating expression of cytokines.
Bae
Eun-Ah
EA
Department of Food and Nutrition, Kyung Hee University, Hoegi, Dongdaemun-ku, Seoul, Korea.
Han
Myung Joo
MJ
Shin
Yong-Wook
YW
Kim
Dong-Hyun
DH
D000818:Animals; D016207:Cytokines / Q000235:genetics; D003877:Dermatitis, Contact / Q000517:prevention & control*; D005260:Female; D036145:Ginsenosides / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D010081:Oxazolone; D005894:Panax; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects*; D010936:Plant Extracts / Q000627:therapeutic use*; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis
D016207:Cytokines; D036145:Ginsenosides; D016328:NF-kappa B; D010936:Plant Extracts; D012333:RNA, Messenger; D010081:Oxazolone; C097367:ginsenoside Rg3; C055305:ginsenoside Rh2; D011451:Prostaglandin-Endoperoxide Synthases; C055328:ginsenoside Rf